MaxCyte, Inc. (MXCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
MXCT Stock Price Chart Interactive Chart >
MXCT Price/Volume Stats
| Current price | $4.81 | 52-week high | $17.44 |
| Prev. close | $4.45 | 52-week low | $4.00 |
| Day low | $4.47 | Volume | 937,400 |
| Day high | $4.81 | Avg. volume | 615,409 |
| 50-day MA | $5.78 | Dividend yield | N/A |
| 200-day MA | $9.58 | Market Cap | 488.41M |
MaxCyte, Inc. (MXCT) Company Bio
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Latest MXCT News From Around the Web
Below are the latest news stories about Maxcyte Inc that investors may wish to consider to help them evaluate MXCT as an investment opportunity.
MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the fourth quarter and full year of 2021 after the U.S. market close on Tuesday, March 22nd, 2022. Company ma |
MaxCyte (MXCT) Investor Presentation - SlideshowNo summary available. |
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that, on February 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 204,500 shares o |
MaxCyte signs strategic platform license to advance tumor infiltrating lymphocyte programsMaxCyte (MXCT) signed a strategic platform license ((SPL)) with Intima Bioscience, a biotech developing genetically engineered cell therapies for solid tumor cancer.Under the terms of |
MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes ProgramsIntima Bioscience to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidatesNEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Intima Bioscience, Inc., a clinical stage biotechnology company develop |
MXCT Price Returns
| 1-mo | -10.59% |
| 3-mo | -29.16% |
| 6-mo | -62.39% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -52.80% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...